Everybody responds differently
Glucagon-like peptide-1 receptor (GLP-1R) agonists, a cornerstone for treating type 2 diabetes mellitus (T2DM) and obesity, are currently considered a promising treatment for MASLD [11, 12]
Because obesity is a complex chronic disease rather than a simple issue of willpower, medicines like retatrutide are usually considered within a structured care plan
In fact, studies show that up to 50% of people using GLP-1 injectables like Ozempic report some form of reaction, many of which are tied to avoidable preparation errors
TripleHormone-Receptor Agonist Retatrutide for Obesity (Jastreboff et al.)
Teaming Sofwave's skin lifting with Pure Impact's muscle-building capabilities directly tackles both common post-GLP-1 concerns, creating a more comprehensive transformation